

Special Issue

New Insights into Cell Death and Drug Resistance in Cancer

Message from the Guest Editor

Investigating drug resistance in cancer treatment is critical to reducing failure rates in cancer treatment and improving patient outcomes. This Special Issue, titled "Insights into cell death and drug resistance in cancer", explores the complex relationships among anti-cancer mechanisms, such as types of cell death, signal transduction pathways, and the emergence of drug resistance in cancer. Understanding the mechanisms involved in the acquisition of drug resistance in cancer cells is essential to overcoming cancer drug resistance and can also facilitate the development of effective therapeutic strategies. To summarize, elucidating the relationship between cell death and drug resistance could improve the effectiveness of cancer treatments, refine therapeutic approaches, and, ultimately, lead to better outcomes for cancer patients.

Guest Editor

Dr. Chuhee Lee

Department of Biochemistry and Molecular Biology, School of Medicine, 170 Hyun-Chung Ro, Yeungnam University, Daegu 42415, Republic of Korea

Deadline for manuscript submissions

closed (28 February 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/197752

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)